Table 1 Clinical data of all subjects included in the analysis
Subject | Type of cancer | Age | Time between scans (months) | Therapy between scans | Bisphosphonates |
|---|---|---|---|---|---|
P001 | Prostate | 77 | 6 | Leuprorelin/bicalutamide | None |
P002 | Breast | 50 | 11 | Tamoxifen | Zolendronate |
P003 | Breast | 62 | 6 | Tamoxifen | Zolendronate |
P004 | Breast | 57 | 11 | Denusomab/everolimus | none |
P005 | Breast | 54 | 24 | Tamoxifen | Zolendronate |
P006 | Breast | 59 | 12 | Fulvestrant | Zolendronate |
P007 | Breast | 48 | 6 | Denusomab | None |
P008 | Breast | 71 | 6 | Anastrazole | Zolendronate |
P009 | Breast | 73 | 11 | Exemastane/everolimus | None |
P010 | Breast | 66 | 12 | None | Zolendronate |
P011 | Breast | 71 | 4 | Denusomab/letrozole | None |
P012 | Breast | 57 | 13 | Anastrazole | None |
P013 | Breast | 44 | 7 | Letrozole | Zolendronate |
P014 | Prostate | 75 | 15 | Abiraterone/goserelin/docetaxelce | Zolendronate |
P015 | Breast | 74 | 3 | Denusomab/afinitor/exemstan | None |
P016 | Breast | 42 | 12 | Eribulin | None |
P017 | Breast | 49 | 12 | Letrozole | None |
P018 | Breast | 71 | 16 | Denosumab/trastuzumab/letrozole | None |
P019 | Prostate | 78 | 14 | Bicalutamide | None |